Association of Stroke Severity With Efficacy of Early Tirofiban Infusion After Intravenous Thrombolysis
Journal of the American Heart Association · 2026-11-12
DOI: 10.1161/jaha.126.049693 ↗Abstract
Background This study aims to assess the effects of stroke severity at admission on the efficacy and safety of early tirofiban infusion following intravenous thrombolysis in patients with acute ischemic noncardioembolic stroke using data from the ASSET‐IT (Advancing Stroke Safety and Efficacy Through Early Tirofiban Administration After Intravenous Thrombolysis) trial. Methods All 832 patients with acute ischemic noncardioembolic stroke from the ASSET‐IT database were included in this exploratory post hoc analysis. The primary efficacy and safety outcomes were an excellent functional outcome (modified Rankin Scale score of 0–1 at 90 days) and intracranial hemorrhage. Results Among the 832 patients included, the median age was 69 (interquartile range, 59–76) years, 531 (63.8%) were men, 367 (44.1%) had minor stroke (National Institutes of Health Stroke Scale score
EUVIMED